McKesson Q2 Revenue Beats Estimates Amid Mixed Healthcare Providers Results

Earnings
โดย Yahoo Finance·US·Read original
Summary · why it matters

McKesson reported second-quarter revenues of $105.4 billion, up 7.7% year over year and 1.2% above analyst expectations, while its stock remained flat at $868.87. Among the 39 healthcare providers and services stocks tracked, aggregate revenues beat consensus by 1.7% and next-quarter guidance came in 1.6% above estimates, yet the group's average share price fell 1.2% since earnings. CVS Health posted the best quarter with revenues of $106.1 billion, up 7.3% and 6.7% above expectations, but its stock dropped 9.1% to $94.90. AdaptHealth was the weakest performer, missing revenue estimates by 12.6% with revenues of $740.3 million and issuing significantly lower full-year revenue and EBITDA guidance, sending its stock down 46.2% to $5.83. Elevance Health reported flat revenues of $49.83 billion, beating estimates by 2.5%, but lost 469,000 customers and saw its stock fall 7.4% to $395.18, while Quest Diagnostics grew revenues 10.2% to $3.04 billion and its stock rose 12.6% to $236.32.

Impact on stocks 5

Health Care · 3 stocks
CVS Health Corp
CVS
▼ NegativeCapitalrelevance

Beat revenue estimates but stock dropped 9.1% despite strong quarter

Aging Population · 1 stocks
Adapthealth Corp
AHCO
▼ NegativeCapitalrelevance

Missed revenue estimates by 12.6% and cut full-year guidance, stock fell 46.2%

Biotech & Genomic Medicine · 1 stocks